Portage Biotech Inc

NASDAQ:PRTGUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

Contact Information

Headquarters

Clarence Thomas Building, Road Town P.O. Box 4649TORTOLA, ON, Virgin Islands (British) VG1110

Phone

416-929-1806

Fax

416-929-6612

Executives

Chairman of the Board, Chief Executive Officer

Ian Walters

Chief Financial Officer, Secretary

Allan Shaw

Chief Scientific Officer

Robert Kramer

Vice President - Project Management and Operations

Steven Innaimo

Vice President - Development

Justin Fairchild